BGM Group Ltd. (BGM) 株式分析

企業概要

BGM Group Ltd. operates primarily as a pharmaceutical and chemical entity within the Chinese market, focusing on the production and distribution of oxytetracycline-based therapeutic products. The company specializes in the manufacturing of Qilian Shan oxytetracycline tablets, which are utilized to prevent and treat various diseases across poultry species such as chickens and turkeys, as well as in cattle, swine, and human applications. This operational scope places BGM Group Ltd. squarely within the broader Healthcare sector, specifically categorized under the industry of Drug Manufacturers - Specialty & Generic. As of the latest reporting data, the company holds a market capitalization of $61.37M, while specific figures for annual revenue and employee count are not publicly disclosed in the current dataset. The relatively modest market cap of $61.37M suggests that the company operates as a small-cap entity with limited market penetration compared to major pharmaceutical conglomerates, indicating a niche presence in the specialized veterinary and generic drug markets rather than a dominant market leader.

財務健全性

The financial statements for BGM Group Ltd. indicate that revenue, net income, and EBITDA figures are currently unavailable or reported as N/A for the trailing twelve months. Consequently, the gap between revenue and net income cannot be quantified directly, yet the reported profit margin of 0.0% implies that the company has not generated net profits on its sales, which often occurs in early-stage growth phases or during periods of significant operational restructuring. Similarly, the free cash flow is listed as N/A, meaning there is no available data to assess the company's immediate financial flexibility for capital expenditures or debt servicing without further disclosure. However, the company maintains a cash balance of $14.54M, which represents a significant liquidity buffer against its reported total debt of $1.78M. The gross margin is recorded at 0.0%, operating margin at -15.6%, and profit margin at 0.0%, a combination that indicates substantial operating costs or losses that are currently exceeding the gross revenue generated. These negative operating margins suggest that the company is burning cash to fund its research, development, or market expansion efforts rather than generating immediate profitability. In terms of leverage, the debt-to-equity ratio stands at 0.97, which implies a moderate level of debt relative to equity, while the balance sheet appears less leveraged given the cash reserve significantly exceeds the debt obligation. The current ratio is not disclosed, preventing an assessment of short-term liquidity relative to current liabilities, but the high cash-to-debt ratio offers a qualitative sense of solvency. Furthermore, the return on equity and return on assets are both N/A, which prevents a direct calculation of management effectiveness in generating returns on the shareholders' capital or the company's asset base at this time.

バリュエーション評価

Valuation multiples for BGM Group Ltd. show a trailing P/E ratio and forward P/E ratio that are both unavailable, preventing a standard earnings-based valuation comparison. The absence of these metrics, coupled with a price-to-book ratio of 0.17, indicates that the market is valuing the company at a significant discount to its book value, a scenario often seen in distressed assets or companies with negative equity or earnings. Since the price-to-sales ratio and EV/EBITDA are also N/A, alternative valuation methods relying on sales or enterprise value multiples are not applicable for this specific dataset. The stock has exhibited extreme volatility, with a 52-week high of $17.17 and a 52-week low of $0.27. Based on the available price metrics, the current trading price sits significantly below the 52-week high, reflecting a sharp decline from peak levels, though the exact percentage requires the current price which is not explicitly defined in the provided facts, but the range itself highlights high risk. The beta value is N/A, so it is impossible to quantify the stock's price volatility relative to the broader market index based on the provided information. The price-to-book of 0.17 specifically suggests that the market assigns very low value to the company's tangible assets, implying that investors are pricing in substantial operational challenges or uncertainty regarding future earnings potential.

Growth & Income

Revenue growth for the trailing twelve months is reported at 13.9%, indicating a year-over-year expansion in top-line sales, whereas earnings growth is N/A due to the lack of reported net income data. The inability to compare earnings growth directly to revenue growth stems from the 0.0% net income and N/A earnings growth figures, suggesting that the top-line expansion has not yet translated into bottom-line profitability. Regarding income distribution, the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This 0.0% payout ratio confirms that the company is retaining all of its available earnings, if any, to reinvest into its operations rather than distributing cash to shareholders. The overall growth and income profile for BGM Group Ltd. is characterized by top-line revenue expansion that has not yet resulted in positive net income, with no dividend income available to investors and a reliance on internal reinvestment for future development.